{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:00:53Z","timestamp":1766048453406},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Huazhong Univ. Sci. Technol. [Med. Sci.]"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s11596-014-1232-1","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T21:52:06Z","timestamp":1391550726000},"page":"59-65","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats"],"prefix":"10.1007","volume":"34","author":[{"given":"Jin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-nian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-bo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,6]]},"reference":[{"issue":"24","key":"1232_CR1","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1056\/NEJM200212123472418","volume":"347","author":"G Famularo","year":"2002","unstructured":"Famularo G, Trinchieri V, De Simone C. Inflammatory bowel disease. N Engl J Med. 2002,347(24):1982\u20131984","journal-title":"N Engl J Med"},{"issue":"9300","key":"1232_CR2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0140-6736(02)07284-7","volume":"359","author":"F Shanahan","year":"2002","unstructured":"Shanahan F. Crohn\u2019s disease. Lancet, 2002,359(9300): 62\u201369","journal-title":"Lancet"},{"issue":"9303","key":"1232_CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(02)07499-8","volume":"359","author":"RJ Farrell","year":"2002","unstructured":"Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet, 2002,359(9303):331\u2013340","journal-title":"Lancet"},{"issue":"5","key":"1232_CR4","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1572-0241.2000.01940.x","volume":"95","author":"RD Cohen","year":"2000","unstructured":"Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol, 2000,95(5):1263\u20131276","journal-title":"Am J Gastroenterol"},{"issue":"Suppl2","key":"1232_CR5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-2036.17.s2.18.x","volume":"17","author":"F Rizzello","year":"2003","unstructured":"Rizzello F, Gionchetti P, Venturi A, et al. Medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther, 2003,17(Suppl 2):7\u201310","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl2","key":"1232_CR6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2036.17.s2.22.x","volume":"17","author":"R L\u00f6fberg","year":"2003","unstructured":"L\u00f6fberg R. Medical treatment of mild to moderately active Crohn\u2019s disease. Aliment Pharmacol Ther, 2003,17(Suppl 2):18\u201322","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl2","key":"1232_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.17.s2.23.x","volume":"17","author":"M Scribano","year":"2003","unstructured":"Scribano M, Prantera C. Medical treatment of moderate to severe Crohn\u2019s disease. Aliment Pharmacol Ther, 2003,17(Suppl 2):23\u201330","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl2","key":"1232_CR8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2036.17.s2.20.x","volume":"17","author":"L Biancone","year":"2003","unstructured":"Biancone L, Tosti C, Fina D, et al. Maintenance treatment of Crohn\u2019s disease. Aliment Pharmacol Ther, 2003,17 (Suppl 2):31\u201337","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl2","key":"1232_CR9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2036.17.s2.12.x","volume":"17","author":"M Cottone","year":"2003","unstructured":"Cottone M, Orlando A, Viscido A, et al. Prevention of postsurgical relapse and recurrence in Crohn\u2019s disease. Aliment Pharmacol Ther, 2003,17(Suppl 2):38\u201342","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl3","key":"1232_CR10","first-page":"III43","volume":"50","author":"M Campieri","year":"2002","unstructured":"Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut, 2002,50(Suppl 3):III43\u2013III46","journal-title":"Gut"},{"issue":"3","key":"1232_CR11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/apt.12369","volume":"38","author":"S Vegter","year":"2013","unstructured":"Vegter S, Tolley K, Wilson Waterworth T, et al. Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol Ther, 2013,38(3): 284\u2013293","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1232_CR12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ibd.23003","volume":"19","author":"DJ Stobaugh","year":"2013","unstructured":"Stobaugh DJ, Deepak P, Thorpe M, et al. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis. Inflamm Bowel Dis, 2013,19(2):301\u2013308","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"1232_CR13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1365-2036.2011.04619.x","volume":"33","author":"MS Harris","year":"2011","unstructured":"Harris MS, Lichtenstein GR. Delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther, 2011,33(9):996\u20131009","journal-title":"Aliment Pharmacol Ther"},{"key":"1232_CR14","first-page":"CD004118","volume":"11","author":"JK Marshall","year":"2012","unstructured":"Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev, 2012,11:CD004118","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"1232_CR15","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/j.1572-0241.2000.02180.x","volume":"95","author":"JK Marshall","year":"2000","unstructured":"Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol, 2000,95(7):1628\u20131636","journal-title":"Am J Gastroenterol"},{"key":"1232_CR16","first-page":"CD000543","volume":"17","author":"BG Feagan","year":"2012","unstructured":"Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, 2012,17;10:CD000543","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1232_CR17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02979057","volume":"22","author":"YS Kim","year":"1999","unstructured":"Kim YS, Son M, Ko JI, et al. Effect of DA-6034, a derivative of flavonoid, on experimental animal models of inflammatory bowel disease. Arch Pharm Res, 1999,22(4):354\u2013360","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1232_CR18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0016-5085(89)90904-9","volume":"96","author":"GP Morris","year":"1989","unstructured":"Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 1989,96(3):795\u2013803","journal-title":"Gastroenterology"},{"issue":"3","key":"1232_CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00042737-200012030-00001","volume":"12","author":"I Padol","year":"2000","unstructured":"Padol I, Huang JQ, Hogaboam CM, et al. Therapeutic effects of the endothelin receptor antagonist Ro 48-5695 in the TNBS\/DNBS rat model of colitis. Eur J Gastroenterol Hepatol, 2000,12(3):257\u2013265","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"1232_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0016-5085(89)90760-9","volume":"96","author":"JL Wallace","year":"1989","unstructured":"Wallace JL, MacNaughton WK, Morris GP, et al. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology, 1989,96(1):29\u201336","journal-title":"Gastroenterology"},{"key":"1232_CR21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0076-6879(90)86172-R","volume":"186","author":"MB Grisham","year":"1990","unstructured":"Grisham MB, Benoit JN, Granger DN. Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol, 1990,186:729\u2013742","journal-title":"Methods Enzymol"},{"issue":"12","key":"1232_CR22","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.bcp.2005.03.024","volume":"69","author":"M S\u00e1nchez-Hidalgo","year":"2005","unstructured":"S\u00e1nchez-Hidalgo M, Mart\u00edn AR, Villegas I, et al. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol, 2005,69(12):1733\u20131744","journal-title":"Biochem Pharmacol"},{"issue":"1\u20132","key":"1232_CR23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0378-4347(98)00323-5","volume":"716","author":"FN Hussain","year":"1998","unstructured":"Hussain FN, Ajjan RA, Moustafa M, et al. Simple method for the determination of 5-aminosalicylic and N-acetyl-5-aminosalicylic acid in rectal tissue biopsies. J Chromatogr B Biomed Sci Appl, 1998,716(1\u20132):257\u2013266","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"6","key":"1232_CR24","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1053\/j.gastro.2004.02.071","volume":"126","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology, 2004,126(6):1582\u20131592","journal-title":"Gastroenterology"},{"issue":"3","key":"1232_CR25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1017987229718","volume":"47","author":"JP Gisbert","year":"2002","unstructured":"Gisbert JP, Gomoll\u00f3n F, Mat\u00e9 J, et al. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci, 2002,47(3):471\u2013488","journal-title":"Dig Dis Sci"},{"issue":"4Pt1","key":"1232_CR26","first-page":"G622","volume":"268","author":"CJ Bell","year":"1995","unstructured":"Bell CJ, Gall DG, Wallace JL. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol, 1995,268(4 Pt 1):G622\u2013G630","journal-title":"Am J Physiol"},{"key":"1232_CR27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.20.100301.064816","volume":"20","author":"W Strober","year":"2002","unstructured":"Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol, 2002,20:495\u2013549","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"1232_CR28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nprot.2007.41","volume":"2","author":"S Wirtz","year":"2007","unstructured":"Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc, 2007,2(3):541\u2013546","journal-title":"Nat Protoc"},{"issue":"1","key":"1232_CR29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm0107-26","volume":"13","author":"MF Neurath","year":"2007","unstructured":"Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med, 2007,13(1):26\u201328","journal-title":"Nat Med"},{"issue":"7","key":"1232_CR30","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1053\/j.gastro.2007.03.104","volume":"132","author":"CO Elson","year":"2007","unstructured":"Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology, 2007,132(7):2359\u20132370","journal-title":"Gastroenterology"}],"container-title":["Journal of Huazhong University of Science and Technology [Medical Sciences]"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-014-1232-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11596-014-1232-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-014-1232-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T13:11:02Z","timestamp":1559394662000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11596-014-1232-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1007\/s11596-014-1232-1","relation":{},"ISSN":["1672-0733","1993-1352"],"issn-type":[{"value":"1672-0733","type":"print"},{"value":"1993-1352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}